Φορτώνει......
Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
Pompe disease results from acid α-glucosidase (GAA) deficiency, and enzyme replacement therapy (ERT) with recombinant human (rh) GAA has clinical benefits, although its limitations include the short half-life of GAA and the formation of antibody responses. The present study compared the efficacy of...
Αποθηκεύτηκε σε:
Τόπος έκδοσης: | Mol Ther Methods Clin Dev |
---|---|
Κύριοι συγγραφείς: | , , , , , , |
Μορφή: | Artigo |
Γλώσσα: | Inglês |
Έκδοση: |
American Society of Gene & Cell Therapy
2017
|
Θέματα: | |
Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5363303/ https://ncbi.nlm.nih.gov/pubmed/28344998 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtm.2016.12.010 |
Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|